
India well-equipped to swiftly detect, contain new COVID variants: Ex-ICMR DG Bhargava
New Delhi: The emergence of the
XFG variant
is part of the SARS-CoV-2 virus's natural evolution, said Prof. (Dr)
Balram Bhargava
, former of Director General of the Indian Council of Medical Research (
ICMR
) and former Secretary of the Department of Health Research.
He added that India is well-positioned to detect and contain emerging variants swiftly due to the widespread deployment of rapid
molecular diagnostic platforms
such as
Truenat
.
As of Tuesday morning, India has reported 6,815 active COVID-19 cases. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), 163 cases of the new COVID-19 variant XFG have recently been detected across the country.
Dr Bhargava said that XFG variant carries mutations that may enhance its ability to bind to human cells and bypass immune defences.
"Early reports suggest that the variant has high immune escape potential, but there is no current evidence to indicate increased severity.
However, as the virus adapts, India's diagnostic infrastructure has adapted since the very first wave. RT-PCR remains the cornerstone of COVID-19 diagnostics, and the widespread deployment of rapid molecular platforms like Truenat puts India in a strong position to detect and contain emerging variants swiftly--even in remote and resource-limited settings," he said.
Dr Bhargava, who played a key role in India's pandemic response, stressed the continued importance of point-of-care testing in identifying emerging variants such as XFG.
"Vigilance is critical now, and not panic. As we've done in the past, we should continue testing when symptomatic, masking in crowded spaces, and staying up to date with vaccinations," he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
35 minutes ago
- The Hindu
GSK partners with Bharat Biotech for Shigella vaccine
Hyderabad-based vaccine maker Bharat Biotech International and global biopharma major GSK have announced a collaboration to advance development of latter's Shigella vaccine candidate altSonflex1-2-3. Under their agreement, Bharat Biotech will lead further development of altSonflex1-2-3, including the Phase 3 clinical trials, regulatory advancement and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding and contributing to the access and delivery plans and commercialisation strategy, the companies said on Thursday, June 12. Shigellosis is an acute human inflammatory disease of the large intestine caused by Gram-negative Shigella. It is characterised by watery diarrhoea, fever, abdominal cramps and pain, and bloody and mucus-filled stools. There is no licenced Shigella vaccine currently available. Now entering Phase 3 trials altSonflex1-2-3 is poised to become the first scalable, affordable and globally accessible vaccine to combat this urgent public health threat, Bharat Biotech said on the in-licensed vaccine candidate. GSK's vaccine candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform and robust early clinical results. It has demonstrated a strong safety and immunogenicity profile in both European and African trials, including in the primary target population of 9-month-old infants, it said. A Phase 1 study in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of nine-month-old infants, the primary target population, reported no safety concerns. Interim results from 2024 confirmed the vaccine candidate met its pre-set immunogenicity goals. 'This collaboration [Shigella vaccine] combines our strengths in innovation, manufacturing and global health commitment. The use of GMMA technology reflects our mission to deliver accessible vaccines that protect and improve lives worldwide,' Bharat Biotech executive chairman Krishna Ella said in a release. GMMA technology uses bacterial outer membranes to deliver the O Antigen to the immune system. This approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations, the company said. GSK's chief global health officer Thomas Breuer said 'the agreement allows us to combine our strengths in science, research, and technology with Bharat Biotech's capacity to develop and deliver vaccines at scale, potentially preventing illness and saving lives around the world'. The collaboration builds on GSK's existing relationship with Bharat Biotech, following a product transfer and license agreement in 2021 for the world's first malaria vaccine, RTS,S.
&w=3840&q=100)

Business Standard
37 minutes ago
- Business Standard
Bharat Biotech, GSK partner to develop vaccine for Shigella diarrhoea
As part of this agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing Press Trust of India New Delhi Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form of bacterial diarrhoea. The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results, it added. "With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said. As part of this agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the Access and Delivery Plans and commercialisation strategy. "This agreement allows us to combine our strengths in science, research, and technology with Bharat Biotech's capacity to develop and deliver vaccines at scale, potentially preventing illness and saving lives around the world," GSK Chief Global Health Officer Thomas Breuer said.


Business Standard
an hour ago
- Business Standard
Active Covid-19 cases cross above 7000 mark in India
India continues to see a steady increase in Covid-19 cases. According to the Ministry of Health and Family Welfare, the active case count has crossed 7,000, with 7,121 active infections right now. Kerala continues to record the highest number of cases, with over 2,200 active cases so far. Powered by Capital Market - Live News